Allied Investment Advisors LLC Grows Stock Holdings in Johnson & Johnson $JNJ

Allied Investment Advisors LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 73,313 shares of the company’s stock after buying an additional 3,132 shares during the quarter. Johnson & Johnson comprises 2.2% of Allied Investment Advisors LLC’s portfolio, making the stock its 16th largest holding. Allied Investment Advisors LLC’s holdings in Johnson & Johnson were worth $13,594,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson in the second quarter worth $27,000. Clayton Financial Group LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at $28,000. Semmax Financial Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth about $35,000. Finally, Signature Resources Capital Management LLC grew its holdings in Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $230.82 on Tuesday. The firm has a market capitalization of $556.11 billion, a PE ratio of 20.89, a price-to-earnings-growth ratio of 2.21 and a beta of 0.35. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The business’s 50-day moving average is $211.21 and its two-hundred day moving average is $192.24. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $231.19.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The business had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. During the same period in the prior year, the firm posted $2.04 earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Analyst Ratings Changes

Several analysts have issued reports on JNJ shares. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Wolfe Research boosted their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Daiwa Capital Markets increased their target price on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Finally, TD Cowen lifted their price objective on shares of Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $233.05.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.